A recombinant lactococcus microcapsule, its preparation method and application

By constructing recombinant Lactococcus lactis microcapsules, integrating CAT and SOD genes and utilizing CS and SA coating, the safety and targeting deficiencies of existing technologies for treating inflammatory bowel disease are addressed. This achieves effective antioxidant and intestinal barrier protection in the gastrointestinal tract, providing a safe and effective treatment strategy.

CN121287651BActive Publication Date: 2026-05-26NORTHEAST AGRICULTURAL UNIVERSITY
2 Cites 0 Cited by

Patent Information

Application Number
CN202511862289.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-12-11
Publication Date
2026-05-26
Estimated Expiration
2045-12-11

AI Technical Summary

Technical Problem

Existing methods for treating or alleviating inflammatory bowel disease suffer from low safety, high side effects, unstable efficacy, and insufficient targeting. Furthermore, orally delivered active substances are difficult to maintain their activity in the harsh environment of the gastrointestinal tract.

Method used

Recombinant Lactococcus lactis microcapsules were constructed by integrating a fusion gene encoding catalase (CAT) and superoxide dismutase (SOD) and coating it with a composite nanomaterial of mucoadhesive chitosan (CS) and sodium alginate (SA). The lacF gene was used as a screening marker to ensure safety and specificity.

Benefits of technology

It improved the survival rate of recombinant lactococcus in harsh environments, enhanced intestinal permeability and microbiota diversity, inhibited pro-inflammatory factors, and increased the expression of anti-inflammatory cytokines, providing a safe and effective treatment strategy for inflammatory bowel disease.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention relates to a recombinant *Lactococcus lactis* microcapsule, its preparation method, and its applications, belonging to the field of genetic engineering. To address the technical problems of low safety, high side effects, unstable efficacy, and insufficient targeting in existing methods for treating or alleviating inflammatory bowel disease (IBD), this invention provides a recombinant *Lactococcus lactis* microcapsule. By integrating a fusion gene encoding catalase and superoxide dismutase, a recombinant *Lactococcus lactis* with antioxidant function is constructed. The recombinant *Lactococcus lactis* is then coated with a mucosa-adhesive chitosan and sodium alginate composite nanomaterial to obtain a microcapsule with antioxidant enzyme expression capabilities and a nano-protective coating. The recombinant *Lactococcus lactis* microcapsule provided by this invention can enhance the activity and bioavailability of orally delivered substances under the harsh acidic environment and complex physiological barriers of the gastrointestinal tract, providing a new strategy and experimental evidence for the clinical prevention and treatment of IBD.
Need to check novelty before this filing date? Find Prior Art